Acute and chronic graft versus host disease (GVHD) are major limiting factors for the success of allogeneic hematopoietic cell transplantation (alloHCT) as curative therapy for haematological malignancies. Though the occurrence of GVHD is controlled in part by non-specific T cell directed immunosuppression, this contributes to disease relapse and increased risk of infections. Dendritic cells (DC) direct immune responses and reinforce regulatory mechanisms. Targeting DC activation as a novel immunosuppressive strategy may limit the generation of deleterious T cell responses and preserve regulatory T cell responses, whilst preserving T cell responses to leukemia and pathogens. We have shown that presence of activated CMRF-44 + CD11c + DC predicts for acute GVHD after clinical alloHCT (Transplantation 2007;83:839). This may reflect systemic activation of blood DC or their migration after activation. Our recent data associating CCR5 expression on CD16 + DC with clinical acute GVHD (submitted) supports the latter concept. Such observations may enable earlier intervention with current agents or potentially new mAb targeting activated DC. Mice with human PBMC xenograft undergoing early graft versus host disease events have CMRF-44 + CD11c + DC. We have shown efficacy of an anti-human CD83 antibody in preventing xenogenic GVHD but preserving protective anti viral and leukemic responses (J Exp Med 2009;206:387). Similar efficacy of anti CD83 antibody in mouse alloHCT was reported recently (BMT 2011;46 Suppl:P837). Our ongoing studies focus on human DC subpopulations in clinical alloHCT. We have now identified activated CMRF-44 + DC in chronic GVHD and shown that they decline with effective extracorporeal photochemotherapy. This justifies the extended evaluation of new human anti CD83 mAb and new CMRF-44 like mAb being developed in our laboratory as potential new immunosuppressive agents. Current studies confirm their ability to inhibit human immune responses in vitro and in vivo and we plan to test these new anti-DC therapeutics in Phase 1 studies in alloHCT.
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Identification and Typing of Killer-Cell Immunoglobulin-Like Receptors (KIRs) Using Quantitative PCR Assay Reagents for Research Persis P. Wadia 1 , Doug Bost 2 . 1 Product Development, Quest Diagnostics, Alameda, CA; 2 Celera, Alameda, CA Aim: Recent publications demonstrate after an allogeneic hematopoietic cell transplant (HCT), anti-leukemia effects are primarily provided by T cells and Natural Killer (NK) cells. NK cells play a role in reduced graft versus host disease and in increased graft versus leukemia effects predominantly due to their cell surface receptors namely Killer-cell immunoglobulin-like receptors (KIRs). Conventional KIR genotyping methods involve sequence-specific primer (SSP)-PCR or sequence specific oligonucleotide hybridization PCR followed by visualization of PCR products by agarose gel electrophoresis or using sequence-based typing. Lack of a universal test to type KIR combined with the low throughput and high costs of existing methodologies prompted the development of a prototype quantitative PCR (qPCR) assay for KIR genotyping. The prototype assay uses fluorescent hydrolysis probes and may provide accurate and fast KIR genotyping with minimal DNA to aid in KIR genotyping for pre and post-transplantation research. Methods: Panel of 24 DNA containing common KIR genotypes was obtained from UCLA DNA exchange. 240 ng total DNA for 16 KIR reactions (each reaction run in triplicate) was used for the prototype qPCR assay and results were compared with a PCR-SSP KIR genotyping kit utilizing 3 ug total DNA. The prototype assay consists of reagents to perform multiplexed KIR genotyping which is amplification of a KIR gene and an internal qPCR reference gene for normalizations, quantification, and confirmation of true absence of KIR genes. Results: The prototype qPCR assay results were 100% concordant with the commercial PCR-SSP kit. The qPCR assay accurately detected each KIR gene with a 12 fold reduction in the amount of DNA required. There was no-post PCR analysis or additional specialized equipment with all KIR genes being amplified under the same thermocycling conditions. Conclusions: We have shown feasibility for a prototype qPCR assay for KIR genotyping that is robust and flexible for both small and large scale genetic analysis studies. With implications of KIR in transplantation (particularly in AML HCT), autoimmune and infectious diseases, and pregnancyrelated complications, faster detection might aid earlier therapy intervention and a more sensitive assay can potentially identify previously unidentified novel associations. Genotyping KIRs using qPCR based assays could be useful in both clinical and basic research settings. CMV disease in patients undergoing allogeneic HCT is a major source of morbidity and mortality. CMV PCR allows for earlier detection of viremia and preemptive anti-viral therapy. A recent study by Milano et al. (Blood 2011) has reported the efficacy of the use of intensive CMV prophylaxis in umbilical cord blood recipients. In this case series (table  below) , we describe 3 patients in whom active CMV disease was detected in the context of a viral load which fluctuated between very low level viremia (<150 copies/ml) and undetectable. The patients (3 males, ages 4-11), all received high risk transplants (2 double cord, 1 9/10 URD) for advanced leukemias. All three received myeloablative doses of total body irradiation and cyclophosphamide and the two cord blood recipients received fludarabine additionally. All patients were CMV sero-positive while their donors were CMV sero-negative. They had symptomatic biopsy-proven CMV disease in various locations including the stomach, gallbladder, sinuses and lung. They were treated with intravenous ganciclovir and Cytogam induction and two transitioned to foscarnet due to myelosuppression. All three recovered from their symptomatic disease, although they continued to have fluctuating positivity of their serum CMV PCR. This experience at a single institution in the last year suggests that although CMV PCR has reduced the need for prophylactic ganciclovir in patients undergoing allogeneic HCT, active infection can develop in high risk patients even with very low level of viremia. Therefore, an intensive prophylactic strategy and treatment of any level of viremia, along with a high index of suspicion for CMV disease is required in high risk patients. Additionally, tissue diagnosis, especially with unusual organ involvement such as gallbladder in our patient, should be obtained when possible.
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Sequential Allogeneic Stem Cell Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome Alzbeta Zavrelova, Jakub Radocha, Miriam Lanska, Pavel Zak. Faculty Hospital Hradec Kralove, IV. department of internal medicine -hematology, Czech Republic Aim: To evaluate this strategy in high risk acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
We treated 17 patients with AML or MDS. This cohort consisted of nine patients who did not reach complete remission, 5 patients who reached complete remission but remained with high burden of residual disease and 3 patients up front transplanted for myelodysplatic syndrome with high blast count. Median age was 54 years (32-65years). Median count of blasts in bone marrow before sequential transplantation was 9% (1-76%). 6 patients were transplanted with HLA identical sibling, 8 patients were transplanted with matched unrelated donor (10/10) and 3 patients had unrelated donor with one mismatch (9/10). Flag-Ida chemotherapy (CHT) (n¼4), 3+7 CHT (n¼7) or CHT based on monotherapy with Cytarabin was used as a cytoreduction. Between cytoreductive CHT and preparative regimen was instituted rest period with median of 5 days (2-14 days). After these days of rest preparative regimen consisted of Fludarabin/Busulfan was initiated. Total dose o Busulfan was 8mg/kg n¼6), 12mg/kg(n¼6) nad 16mg/kg (n¼5). Thymoglobulin (total dose 7,5mg/kg) was used in case of unrelated donor in days -3 to -1. Results: Estimated overall survival at 2 years was 67,6%. Whole regimen was tolerated very well even with the highest dose of Busulfan. Transplant related mortality at 100 days was 6% (1 patient with insufitient engraftment died due to infection). 5 patients relapsed after transplantation, 1 patient progressed after transplantation. From these patients just 1 patient did not die due to relapse and was succesfully rescued with chemotherapy and donor lymphocyte infusion. Conclusion: Sequential transplantation is our method of choice in high risk AML and MDS. We demonstrate very low transplant related mortality and promising long term survival of this cohort of high risk patients. 
